Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

PaperCitations, authors & open-access status

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 754 citations, 2016 year and hybrid oa status.

754
Citations
2016
Year
hybrid
OA Status

Related on ScholarIQ

Rima Nabbout
Author
The Lancet
Journal
Tuberous Sclerosis Complex Research
Topic
Tuberous Sclerosis Complex Research
Topic
PI3K/AKT/mTOR signaling in cancer
Topic
Renal cell carcinoma treatment
Topic
470M+ articles · free account